July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
The intracameral fibrinolytic capacity and toxicity of Desmoteplase compared to tissue plasminogen activator in a rabbit model
Author Affiliations & Notes
  • Katrin Voelter
    Veterinary Ophthalmology, Equine Clinic, Vetsuisse Faculty, University of Zurich, Switzerland, Zurich, Switzerland
  • Christoph Tappeiner
    Ophthalmology, Inselspital, Bern University Hospital, Bern, Switzerland
  • Karina Klein
    Center for Applied Biotechnology and Molecular Medicine, University of Zurich, Zurich, Switzerland
  • Nicole Borel
    Pathology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
  • Deborah Bruetsch
    Veterinary Ophthalmology, Equine Clinic, Vetsuisse Faculty, University of Zurich, Switzerland, Zurich, Switzerland
  • Fernando Laguna Sanz
    Hospital Veterinario Puchol, Madrid, Spain
  • Simon Pot
    Veterinary Ophthalmology, Equine Clinic, Vetsuisse Faculty, University of Zurich, Switzerland, Zurich, Switzerland
  • Footnotes
    Commercial Relationships   Katrin Voelter, None; Christoph Tappeiner, None; Karina Klein, None; Nicole Borel, None; Deborah Bruetsch, None; Fernando Laguna Sanz, None; Simon Pot, None
  • Footnotes
    Support  ECVO research grant 2016, Symphasis grant 2016
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2527. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Katrin Voelter, Christoph Tappeiner, Karina Klein, Nicole Borel, Deborah Bruetsch, Fernando Laguna Sanz, Simon Pot; The intracameral fibrinolytic capacity and toxicity of Desmoteplase compared to tissue plasminogen activator in a rabbit model. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2527.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Tissue plasminogen activator (t-PA), injected intracamerally, is the gold standard to resolve fibrin in the anterior chamber. A drug with better corneal permeability to allow topical application would be desirable. Therefore, Desmoteplase (DSPA) was evaluated as alternative regarding ocular permeation, fibrinolytic efficacy and toxicity after topical and intracameral application.

Methods : First, permeation of DSPA (1.4mg/ml) through corneoscleral tissues of different species was evaluated in a diffusion chamber in vitro. Second, fibrin clots were induced in the left anterior chamber of 44 female New Zealand White rabbits, followed by drug application 24 hours (h) after clot induction. DSPA eyedrops (2 mg/ml) were compared to carrier solution in a multiple drop regimen (n=8 per group). Intracameral injections of DSPA (0.6 µg) and t-PA (25 µg) were evaluated for their fibrinolytic efficacy (n=14 per group). Drug efficacy was measured by clot size reduction over 24h. Right eyes served as negative controls. Biocompatibility was evaluated via ophthalmic examinations. Animals were euthanized 48h after clot induction, toxicity was determined histologically. D-dimer levels in aqueous humor were analysed via enzyme-linked immunosorbent assays. Statistical evalution was performed using the Mann-Whitney U Test, ordinal mixed effects and mixed linear models.

Results : DSPA permeated through all tissues ex vivo. In vivo evaluation of topical treatment effect was therefore pursued. No significant differences in clot size reduction at 24h were seen between topically treated groups (Mean +/- SD: 60% +/- 25% (DSPA), 40% +/- 23% (carrier), p=0.2) and between intracameral groups (97% +/- 9% (DSPA), 100% +/- 0% (t-PA), p=0.2) at the tested drug concentrations. While no differences in clinical signs were observed between topical groups, t-PA treated animals demonstrated significantly more symptoms compared to DSPA treated animals. Histologically, no toxic effects were observed in any globe. D-dimer levels were not significantly different between groups and timepoints.

Conclusions : At the tested concentrations, DSPA is a promising fibrinolytic drug with similar fibrinolytic efficacy at 24h post application and fewer side effects than t-PA when injected into the anterior chamber of rabbit eyes.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×